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Edited by Masayuki MiyasakaAbstract CCL15 is a novel human CC chemokine and exerts
its biological activities on immune cells through CCR1 and
CCR3. Because a number of chemokines induce angiogenesis
and endothelial cells express CCR1 and CCR3, we investigated
the angiogenic activity of CCL15. Both CCL15(1-92) and N-
terminal truncated CCL15(25-92) stimulate the chemotactic
endothelial cell migration and diﬀerentiation, but CCL15(25-92)
is at least 100-fold more potent than CCL15(1-92). Treatment
with pertussis toxin (PTX), with anti-CCR1, or with anti-CCR3
antibody inhibits the CCL15(25-92)-induced endothelial cell
migration. CCL15(25-92) also stimulates sprouting of vessels
from aortic rings and mediates angiogenesis in the chick
chorioallantoic membrane assay. Our ﬁndings demonstrate that
CCL15(25-92) has in vitro and in vivo angiogenic activity, and
suggest roles of the chemokine in angiogenesis.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: Chemokine; CCL15; Endothelial cells;
Angiogenesis; CCR1; CCR31. Introduction
Chemokines play central roles in diverse biochemical and
physiological events including regulation of leukocyte traf-
ﬁcking, immunity, and hematopoiesis [1,2]. Chemokines are
subdivided into four distinct groups based on the arrangement
of the two conserved N-terminal cysteine residues: CXC (a),
CC (b), C (c), and CX3C (d). CCL15, also named Leukotactin-
1 (Lkn-1), MIP-1d, MIP-5, HCC-2, and NCC-3, is a novel
human CC chemokine [3]. Mature CCL15 is composed of
predicted 92 amino acid residue and has long amino acid
residues preceding the ﬁrst cysteine at the NH2 terminus [4,5].
It has been reported that N-terminal deletion upto 28 amino
acids of CCL15 increased the agonistic potency on CCR1 and
CCR3 [6]. Although their biochemical and biological activities* Corresponding authors. Fax: +82-54-279-8611 (Y.S. Gho);
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doi:10.1016/j.febslet.2004.06.023are diﬀerent, all the intact and truncated forms bind to both
CCR1 and CCR3, and induce chemotaxis and calcium ﬂux
[4,6]. The biological signiﬁcance of truncated forms of CCL15
is not known yet.
In addition to their functions in leukocyte traﬃcking and
activation, growing evidence suggests that members of the
chemokine family regulate angiogenesis. A number of CXC
chemokines has been reported to either induce endothelial cell
migration and/or proliferation in vitro and neovascularization
in vivo or to act as angiostatic molecules [7,8]. Among the CC
chemokine family reported to date, CCL1 (I-309), CCL2
(MCP-1), CCL11 (eotaxin), and CCL16 (NCC-4) have been
proven to play a direct role in angiogenesis [9–12]. Although
CCL15 exerts important roles in inﬂammation, its role in ne-
ovascularization has not been examined. Here, we demonstrate
that CCL15(25-92) has more potent chemotactic activity for
the endothelial cell than the intact form of CCL15 and has in
vitro and in vivo angiogenic activity.2. Materials and methods
2.1. Materials
Recombinant CCL15 proteins, bFGF, anti-CCL15, anti-CCR1, and
anti-CCR3 antibodies were from R&D Systems (Minneapolis, MN).
Matrigel and rat tail type I collagen were from Collaborative Bio-
medical Products (Bedford, MA). Thermonox disks were from Nunc
(Naperville, IL). Protein A-Sepharose and PTX were from Amersham
Pharmacia Biotech (Uppsala, Sweden) and BIOMOL Research Lab-
oratories (Plymouth Meeting, PA), respectively. Human ﬁbrosarcoma
HT1080 conditioned medium was prepared as described previously
[13].
2.2. Preparation of immuno-depleted and heat-inactivated CCL15
For immuno-depletion, a mixture of either CCL15(25-92) (0.5 lg) or
bFGF (0.5 lg) and 10 lg of either anti-CCL15 monoclonal antibody
or control isotype-matched mouse IgG1 in 0.25 ml of RPMI 1640
containing 0.1% BSA was incubated for 2 h and then incubated with
1:1 slurry of Protein A-Sepharose beads (0.2 ml) overnight at 4 C.
Then, the supernate was aliquoted and stored at )80 C until use. For
heat-inactivation, CCL15(25-92) (10 lg/ml in PBS) was boiled for 10
min, placed on ice, and then stored at )80 C until use.
2.3. Cell migration assay
Human umbilical vein endothelial cells (HUVECs) and immortal-
ized human microvascular endothelial cells (HMEC-1s) and HUVECsblished by Elsevier B.V. All rights reserved.
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checkerboard assays were performed in 48-well microchemotaxis
chambers (Neuro Probe, Inc., Cabin John, MD) [16]. The bottom
chamber was loaded with 30 000 cells, and polyester membrane (Neuro
Probe, Inc.) was laid over the cells. The microchamber was then in-
verted and incubated at 37 C for 2 h. The upper wells were then
loaded with RPMI 1640 containing 0.1% BSA and CCL15. The
chamber was reincubated at 37 C for 2 h, and the ﬁlters were ﬁxed and
stained using Diﬀ-Quick (Baxter Healthcare Corp., McGraw Park,
IL). Each condition was studied in triplicate wells, and each experi-
ment was performed three times. Checkerboard assays were carried out
as described above, except various amounts of CCL15 were placed in
the top and/or bottom wells.
2.4. Endothelial cell proliferation assay
The proliferation assay of endothelial cells was performed by BM 5-
bromo-20-deoxy-uridine (BrdU) labeling and Detection Kit from
Roche (Indianspolis, IN). HUVEC cells (1 104) were seeded in each
well of a gelatin-coated 96-well plates for 24 h at 37 C. After removing
medium, cells were starved for 6 h and then added RPMI 1640 con-
taining 5% FBS and CCL15 at various concentration for 18 h at 37 C.
The bFGF (5 ng/ml) were used as positive control. The each well was
added BrdU labeling solution, washed and ﬁxed precooled ethanol
ﬁxative at )20 C and then added nuclease solution, following anti-
BrdU-POD. The DNA that integrated BrdU was quantitated by rel-
ative luminescence (RLU) of each well using Wallac Victor2 1420
Multilabel counter (Perkin Elmer, Norwalk, CT).
2.5. Capillary-like tube formation assay
Tube formation assay was performed as described previously [16].
Brieﬂy, HUVECs (40 000 cells) in 0.4 ml of serum-free RPMI 1640
medium with varying concentrations of CCL15 were added to each
well coated with 1:1 mixture of RPMI 1640 and Matrigel. bFGF was
added at a concentration of 5 ng/ml as a positive control. After 3 h
incubation, two randomly chosen ﬁelds (20) from each sample were
photographed and total tube areas were analyzed by the Scion Image
program.Fig. 1. CCL15 stimulates migration of human endothelial cells. (A) CCL15(2
presence of medium alone. *, P < 0:05; **, P < 0:01 versus medium alone. (B
manner. *, P < 0:05 versus medium alone. (C) Samples immuno-depleted
activity compared to that of isotype-matched mouse IgG treated samples (j),
as that absorbed with the control IgG. *, P < 0:01 versus mouse IgG treated
reduced migratory activity compared to that of untreated CCL15(25-92) (j).
at diﬀerent concentrations of CCL15 was compared with that observed in the
which were used as positive controls. *, P < 0:01 versus basal proliferatio
valuesS.D. from quadruplicates and are representative of at least three ex2.6. Rat aortic ring assay
Rat aortic ring assay was described previously [17]. Thoracic and
abdominal aortas were obtained from male rats of 6 week age. Plates
(48-well) were coated with 150 ll of Matrigel, and then Matrigel was
gelled at 37 C incubator. The rings of sectioned aortas were placed
into the wells and sealed with 50 ll of Matrigel. CCL15 was added to
the well in 200 ll of human endothelial serum free medium (Gibco-
BRL). Heat-treated CCL15, bFGF, and medium alone were assayed as
controls. After 6 days, aortas were ﬁxed and stained with Diﬀ-Quick.
The assay was scored from 0 (least positive) to 4 (most positive) in a
double blinded manner.
2.7. Chick chorioallantoic membrane assay
To investigate the in vivo angiogenic activity of CCL15, the modiﬁed
chorioallantoic membrane (CAM) assay was carried out as described
previously [16]. Brieﬂy, 10 ll of test samples in type I collagen were
applied onto Thermonox disks and polymerized at room temperature.
The discs were loaded onto the CAM of 10-day-old embryos. After
70 4 h incubation at 37 C, the area around the loaded disk was
photographed with a Nikon digital camera and the number of newly
formed vessels was counted by two observers in a double blinded
manner.3. Results
3.1. CCL15 stimulates human endothelial cell migration
The migratory activities of two diﬀerent forms of CCL15 on
human endothelial cells were tested using Boyden chamber
migration assays. Our results demonstrated that both forms of
CCL15 induced endothelial cell migration in a dose-dependent
manner and that CCL15(1-92), the mature form of CCL15 was
less potent than that of CCL15(25-92) (Fig. 1(A) and (B)),
indicating that truncation of N-terminal region of CCL15 re-5-92) signiﬁcantly induces migration of HUVEC over migration in the
) CCL15(1-92) also induces migration of HUVEC in a dose-dependent
with anti-CCL15 antibody () show signiﬁcantly reduced migratory
but bFGF (5 ng/ml) absorbed with anti-CCL15 antibody was as active
CCL15(25-92). (D) Heat-treated CCL15(25-92) () shows signiﬁcantly
*, P < 0:05 versus untreated CCL15(25-92). (E) HUVEC proliferation
presence of medium alone (negative control,Q) or bFGF (5 ng/ml, ),
n in the presence of medium alone. The data are expressed as mean
periments.
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endothelial cells. Endothelial cell migration stimulated by 10
ng/ml of CCL15(25-92) was similar to the levels observed for
the positive control, bFGF at 5 ng/ml (data not shown). The
maximal chemotactic responses for CCL15(25-92) and
CCL15(1-92) were observed at 10 ng/ml and at 1 lg/ml, re-
spectively. CCL15(25-92) also induced the migration of im-
mortalized human microvascular endothelial cells, HMEC-1
with a response comparable to that observed with HUVECs
(data not shown). CCL15(25-92) treated with anti-CCL15
antibody and heat-treated CCL15 was less active for HUVEC
(Fig. 1(C) and (D), respectively), indicating that migration of
HUVECs was induced speciﬁcally by CCL15.
We next determined whether CCL15 was stimulating endo-
thelial cell migration by chemoattraction (directional migra-
tion) or chemokinesis (random motility). Checkerboard assays
were performed with various concentration of CCL15 in the
top chamber, in the bottom chamber, or in both chambers in
triplicate samples at least three separate experiments. CCL15
stimulates the chemotactic cell migration of HUVECs (data
not shown), indicating that CCL15 induces directional mi-
gration of HUVECs, not a random migration.
Because several angiogenic factors induce endothelial cell
proliferation, we next investigated whether CCL15 has a mi-
togenic eﬀect on endothelial cells using the 5-bromo-20-deoxy-
uridine assay. The presence of CCL15 at concentrations upto 1
lg/ml did not show any eﬀect on DNA synthesis by human
endothelial cells (Fig. 1(E)). These results indicate that CCL15
may not act as a mitogen on endothelial cells.Fig. 2. CCL15 induces the chemotactic response of human endothelial
cells through CCR1 and CCR3. (A) The eﬀect of PTX on HUVEC
migration induced by CCL15(25-92) (10 ng/ml,P), bFGF (5 ng/ml,j)
and HT1080 conditioned medium (). Results are expressed as the
percentage migration of untreated versus PTX-treated endothelial
cells. *, P < 0:05. (B) The eﬀect of anti-CCR1 (10 lg/ml, ), anti-
CCR3 IgG (10 lg/ml, P), or mixture of anti-CCR1 and anti-CCR3
IgG (M) on CCL15(25-92)-induced migration of HUVEC was inves-
tigated. Treatment of isotype-matched mouse (10 lg/ml, j), rat IgG
(10 lg/ml, j), or mixture of mouse and rat IgG (N) shows no eﬀect on
the CCL15-induced HUVEC migration. Q, no treatment. *, P < 0:05;
**, P < 0:01 versus control IgG treated endothelial cells. The data are
mean values S.D. from quadruplicates and are representative of at
least three experiments.3.2. CCL15 induces the chemotactic response of human
endothelial cells through CCR1 and CCR3
Because several studies suggested that CCL15 displayed its
biological activities via binding to CCR1 and CCR3 [4,6]
and human endothelial cells expressed both CCR1 and
CCR3 [11], we investigated whether CCL15 induced the
chemotactic response of endothelial cells through CCR1 and
CCR3 which belong to the seven-transmembrane Gi/G0
protein-coupled receptor (GPCR) family and are sensitive to
pertussis toxin (PTX). PTX eﬃciently blocked CCL15(25-
92)-induced endothelial cell migration, but did not aﬀect the
migratory activity of either bFGF or HT1080-conditioned
medium (Fig. 2(A)). These results suggest that CCL15 exerts
its eﬀect through a receptor linked to PTX-sensitive Gi/G0
family G proteins. As shown in Fig. 2(B), treatment of the
cells with anti-CCR1 or anti-CCR3 antibody alone eﬀec-
tively reduced CCL15(25-92)-induced HUVEC migration.
CCL15-induced HUVEC migration was completely abol-
ished by the presence of both anti-CCR1 and anti-CCR3
antibodies. These data demonstrate that both CCR1 and
CCR3 are indeed functional receptors important for endo-
thelial cell migration to CCL15.3.3. CCL15 promotes endothelial cell diﬀerentiation
We next examined the ability of CCL15 to promote the
formation of capillary-like structures by endothelial cells on
basement membrane Matrigel. This assay can evaluate endo-Fig. 3. CCL15 promotes endothelial cell diﬀerentiation. HUVECs were
seeded on Matrigel and incubated in the presence of diﬀerent con-
centrations of CCL15(25-92) or medium alone. bFGF was used as a
positive control. After 3 h, cells were photographed using an inverted
phase contrast microscope. (A) Representative photographs of vehicle,
CCL15(25-92) (10 ng/ml), heated CCL15(25-92) (10 ng/ml), and bFGF
(10 ng/ml). (B) Quantiﬁcation of newly formed tube in the presence of
diﬀerent concentrations of CCL15(25-92) (j) was compared with that
observed in the presence of either medium alone (Q), heated
CCL15(25-92) (P) or bFGF (). *, P < 0:01 versus medium alone; **,
P < 0:01 versus CCL15(25-92) (10 ng/ml). The data are mean val-
ues S.D. from triplicates and are representative of three independent
experiments.
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neovascularization. CCL15 stimulated tube formation by
HUVECs (Fig. 3). The presence of CCL15(25-92) at 0.1, 1, 10,
and 100 ng/ml showed 1.7-, 2.5-, 2.9-, and 2.4-fold increases,
respectively, in tube area over control medium alone. The ac-
tivity observed with CCL15(25-92) is comparable with that of
the potent angiogenic molecule bFGF (2.9-fold increase),
while CCL15(25-92) pretreated with heat was not active for
HUVEC (Fig. 3), indicating that tube formation of HUVECs
was due to the CCL15. These results suggest that CCL15 may
be angiogenic.Fig. 5. CCL15 induces neovascularization in the chick CAM assay.
CCL15(25-92) or bFGF was loaded on the CAMs of day 10 chick
embryos. After 70 4 h incubation, a fat emulsion was injected under
the CAMs for better visualization of the vessels. Disks and sur-
rounding CAMs were photographed. (A) Representative photographs
of vehicle, CCL15(25-92) (10 ng/egg), heated CCL15(25-92) (10 ng/3.4. CCL15(25-92) induces angiogenesis
To investigate the ex vivo angiogenic activity of CCL15(25-
92), we used a rat aortic ring-sprouting assay. CCL15(25-92)
stimulated vessel sprouting above background levels in a dose-
dependent manner, while CCL15(25-92) pretreated with heat
was not aﬀected vessel sprouting (Fig. 4).
Because CCL15 stimulated migration and diﬀerentiation of
endothelial cells in vitro and sprouting from explanted aorta
rings ex vivo, we next examined whether CCL15(25-92) stim-
ulated angiogenesis in vivo using the chick CAM assay.
CCL15(25-92) signiﬁcantly induced neovascularization from
pre-existing blood vessels (Fig. 5). In association with angio-
genesis, CCL15(25-92) induced an inﬂammatory response as
indicated by an area with increased opacity on the disksFig. 4. CCL15 promotes sprouting from rat aortic rings on Matrigel.
Rat aortas were seeded on Matrigel and incubated in the presence of
diﬀerent concentrations of CCL15(25-92) or medium alone. bFGF was
used as a positive control. After 6 days, aortas were ﬁxed and pho-
tographed. (A) Representative photographs of vehicle, CCL15(25-92)
(10 ng/ml), heated CCL15(25-92) (10 ng/ml), and bFGF (100 ng/ml).
(B) Cell sprouting in the presence of diﬀerent concentrations of
CCL15(25-92) (j) was compared with that observed in the presence of
either medium alone (Q), heated CCL15(25-92) (P) or 100 ng/ml
bFGF (). * P < 0:05; P < 0:01 versus medium alone; ***, P < 0:01
versus CCL15(25-92) (10 ng/ml). The data are mean valuesS.D.
(n ¼ 5) and are representative of two experiments.
egg), and bFGF (100 ng/egg). (B) Quantiﬁcation of newly formed
blood vessels. *, P < 0:01 versus vehicle **, P < 0:01 versus
CCL15(25-92) (10 ng/ml). Twelve to ﬁfteen eggs were used for each
data point and mean values S.D. are shown.(Fig. 5(A)). The presence of 0.1, 1, 10, and 100 ng of
CCL15(25-92) per egg caused 1.7-, 2.1-, 2.6-, and 2.0-fold in-
creases, respectively, in the number of newly formed blood
vessels compared with that of PBS alone or with that of heat-
treated CCL15 (Fig. 5(B)). The angiogenic activity observed
with CCL15(25-92) was comparable to that of the angiogenic
molecule bFGF. These results indicate that CCL15(25-92) is a
potent angiogenic factor in vivo.4. Discussion
In this report, we demonstrate that CCL15 has in vitro and
in vivo angiogenic activity. CCL15(25-92) induced the migra-
tion of human endothelial cells, such as HUVEC and HMEC-1
that are of two diﬀerent tissue origins. Although CCL15(1-92)
induced endothelial cell migration, its chemotactic activity is
less potent than that of CCL15(25-92). Checkerboard assays
indicate that CCL15(25-92) induces endothelial cell migration
in a chemotactic, not a chemokinetic manner. The angiogenic
eﬀect of CCL15 was clearly evident in both the in vitro Ma-
trigel tube formation assay and the in vivo CAM assay. An-
giogenic responses in the chick systems by CCL15 indicate that
chick CCR1 and/or CCR3 homologous to human receptors
may exist. CCL15 can also induce endothelial cell sprouting
from rat aortic rings in the absence of inﬂammatory inﬁltrates,
indicating its direct eﬀect in promoting angiogenesis. The fact
that CCL15 does not act as an endothelial cell mitogen sug-
gests that the chemotactic, not the mitogenic, eﬀect of CCL15
may be responsible for its angiogenic activity. Recently, it has
J. Hwang et al. / FEBS Letters 570 (2004) 47–51 51been reported that NCC-4, also known as CCL16, has in vitro
and in vivo angiogenic activity by activating CCR1 [12]. Al-
though we could not completely exclude the involvement of the
other receptors, these results suggest that the angiogenic ac-
tivity of CCL15 may be mediated via CCR1 and/or CCR3
present on endothelial cells.
Several lines of evidence suggest that a large number of CXC
and CC chemokines play an important role in the regulation of
endothelial cell function and neovascularization, including
proliferation, migration, and diﬀerentiation during angiogen-
esis, and re-endothelialization after injury [7–11,18,19]. In re-
cent years, the involvement of leukocyte inﬁltration in both
physiologic and pathologic angiogenesis has attracted much
attention [8]. CCL15, a classical inﬂammatory chemokine, is
involved in the immune response via attraction of almost all
types of inﬂammatory cells. It has been reported that CCL15
could be a novel mediator of atherosclerosis, indicating that
CCL15 may be involved in vascular disease [20].
Several forms of CCL15, including CCL15(1-92) and
CCL15(25-92), have been studied to characterize the biological
activity of this chemokine [4,6,21,22]. We showed that trun-
cated CCL15(25-92) had more potent migratory activity with
endothelial cells than CCL15(1-92). Our observations are
consistent with reports showing that truncation of NH2-ter-
minal amino acids signiﬁcantly increases the biochemical and
biological activities of CCL15 [6]. Ckb8(25-99) is also more
potent in its agonistic activities than Ckb8(1-99) [23]. Several
forms of circulating HCC-1, including intact HCC-1(1-74) and
HCC-1(9-74), were isolated from plasma [22,24]. In vitro
experiments [24,25] showed that proteolysis of full-length
HCC-1(1-74) by either trypsin or serine proteases present in
conditioned media from several tumor cell lines generated the
active HCC-1(9-74). The biological activity of HCC-1(9-74) is
signiﬁcantly higher than that of HCC-1(1-74), suggesting that
proteolytic processing may transform a virtually inactive
propeptide into a biologically active molecule. Amino-terminal
truncation or elongation of chemokines frequently results in
either signiﬁcant enhancement or loss of activity, the appear-
ance of antagonistic activity, or a change in chemokine re-
ceptor speciﬁcity [22]. Several circulating forms of CCL15 exist
in the blood and act on hematopoietic progenitor cells [26]. To
delineate the biological signiﬁcance of truncated forms of
CCL15, it may be most important to determine whether
CCL15 can be cleaved in vivo by proteolytic enzymes such as
plasminogen activators of urokinase type or metalloprotein-
ases which are overexpressed in cancer. In addition, isolation
of the naturally occurring CCL15 needs to be further eluci-
dated because amino terminus of natural CCL15 has not yet
been determined.
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